Cellosaurus logo
expasy logo

Cellosaurus NYH/187/162 (CVCL_0B24)

[Text version]
Cell line name NYH/187/162
Synonyms NYH/187
Accession CVCL_0B24
Resource Identification Initiative To cite this cell line use: NYH/187/162 (RRID:CVCL_0B24)
Comments Selected for resistance to: ChEBI; CHEBI:50223; (+)-dexrazoxane (Cardioxane; ICRF-187).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Disease Lung small cell carcinoma (NCIt: C4917)
Small cell lung cancer (ORDO: Orphanet_70573)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_8207 (GLC-2)
Sex of cell Male
Age at sampling 41Y
Category Cancer cell line
Publications

PubMed=10416608
Wessel I., Jensen L.H., Jensen P.B., Falck J., Rose A., Roerth M., Nitiss J.L., Sehested M.
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Cancer Res. 59:3442-3450(1999)

PubMed=12044890; DOI=10.1016/S0014-5793(02)02805-3
Wessel I., Jensen L.H., Renodon-Corniere A., Sorensen T.K., Nitiss J.L., Jensen P.B., Sehested M.
Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
FEBS Lett. 520:161-166(2002)

Cross-references
Encyclopedic resources Wikidata; Q54931215
Entry history
Entry creation10-Apr-2015
Last entry update29-Jun-2023
Version number8